vs
HAEMONETICS CORP（HAE）与PREFORMED LINE PRODUCTS CO（PLPC）财务数据对比。点击上方公司名可切换其他公司
HAEMONETICS CORP的季度营收约是PREFORMED LINE PRODUCTS CO的2.0倍（$346.4M vs $173.1M），HAEMONETICS CORP净利率更高（28.1% vs 4.9%，领先23.2%），HAEMONETICS CORP同比增速更快（4.8% vs 3.6%），HAEMONETICS CORP自由现金流更多（$209.9M vs $11.8M），过去两年PREFORMED LINE PRODUCTS CO的营收复合增速更高（10.8% vs 1.5%）
豪洛捷（Haemonetics）是全球血液与血浆供应及服务提供商，于20世纪70年代由艾伦·（杰克）·莱瑟姆博士在马萨诸塞州内蒂克创立，业务围绕血液相关产品及配套服务展开，为全球医疗领域提供血液管理相关的专业解决方案。
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
HAE vs PLPC — 直观对比
营收规模更大
HAE
是对方的2.0倍
$173.1M
营收增速更快
HAE
高出1.2%
3.6%
净利率更高
HAE
高出23.2%
4.9%
自由现金流更多
HAE
多$198.1M
$11.8M
两年增速更快
PLPC
近两年复合增速
1.5%
损益表 — Q4 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $346.4M | $173.1M |
| 净利润 | $97.3M | $8.4M |
| 毛利率 | 57.2% | 29.8% |
| 营业利润率 | 36.1% | 6.8% |
| 净利率 | 28.1% | 4.9% |
| 营收同比 | 4.8% | 3.6% |
| 净利润同比 | — | -19.3% |
| 每股收益（稀释后） | — | $1.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HAEPLPC
| Q1 26 | $346.4M | — | ||
| Q4 25 | $339.0M | $173.1M | ||
| Q3 25 | $327.3M | $178.1M | ||
| Q2 25 | $321.4M | $169.6M | ||
| Q1 25 | $330.6M | $148.5M | ||
| Q4 24 | $348.5M | $167.1M | ||
| Q3 24 | $345.5M | $147.0M | ||
| Q2 24 | $336.2M | $138.7M |
净利润HAEPLPC
| Q1 26 | $97.3M | — | ||
| Q4 25 | $44.7M | $8.4M | ||
| Q3 25 | $38.7M | $2.6M | ||
| Q2 25 | $34.0M | $12.7M | ||
| Q1 25 | $58.0M | $11.5M | ||
| Q4 24 | $37.5M | $10.5M | ||
| Q3 24 | $33.8M | $7.7M | ||
| Q2 24 | $38.4M | $9.4M |
毛利率HAEPLPC
| Q1 26 | 57.2% | — | ||
| Q4 25 | 59.7% | 29.8% | ||
| Q3 25 | 59.5% | 29.7% | ||
| Q2 25 | 59.8% | 32.7% | ||
| Q1 25 | 58.4% | 32.8% | ||
| Q4 24 | 55.5% | 33.3% | ||
| Q3 24 | 54.2% | 31.1% | ||
| Q2 24 | 52.0% | 31.9% |
营业利润率HAEPLPC
| Q1 26 | 36.1% | — | ||
| Q4 25 | 19.9% | 6.8% | ||
| Q3 25 | 17.9% | 7.4% | ||
| Q2 25 | 16.8% | 10.1% | ||
| Q1 25 | 21.6% | 8.8% | ||
| Q4 24 | 16.9% | 10.5% | ||
| Q3 24 | 15.0% | 7.1% | ||
| Q2 24 | 11.8% | 8.1% |
净利率HAEPLPC
| Q1 26 | 28.1% | — | ||
| Q4 25 | 13.2% | 4.9% | ||
| Q3 25 | 11.8% | 1.5% | ||
| Q2 25 | 10.6% | 7.5% | ||
| Q1 25 | 17.5% | 7.8% | ||
| Q4 24 | 10.8% | 6.3% | ||
| Q3 24 | 9.8% | 5.2% | ||
| Q2 24 | 11.4% | 6.8% |
每股收益（稀释后）HAEPLPC
| Q1 26 | — | — | ||
| Q4 25 | $0.95 | $1.72 | ||
| Q3 25 | $0.81 | $0.53 | ||
| Q2 25 | $0.70 | $2.56 | ||
| Q1 25 | $1.17 | $2.33 | ||
| Q4 24 | $0.74 | $2.13 | ||
| Q3 24 | $0.66 | $1.54 | ||
| Q2 24 | $0.74 | $1.89 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $245.4M | — |
| 总债务越低越好 | $1.2B | $38.3M |
| 股东权益账面价值 | $796.3M | $475.5M |
| 总资产 | $2.4B | $653.6M |
| 负债/权益比越低杠杆越低 | 1.53× | 0.08× |
8季度趋势，按日历期对齐
现金及短期投资HAEPLPC
| Q1 26 | $245.4M | — | ||
| Q4 25 | $363.4M | — | ||
| Q3 25 | $296.4M | — | ||
| Q2 25 | $292.9M | — | ||
| Q1 25 | $306.8M | — | ||
| Q4 24 | $320.8M | — | ||
| Q3 24 | $299.3M | — | ||
| Q2 24 | $344.4M | — |
总债务HAEPLPC
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $38.3M | ||
| Q3 25 | $1.2B | $36.0M | ||
| Q2 25 | $1.2B | $31.8M | ||
| Q1 25 | $1.2B | $29.1M | ||
| Q4 24 | — | $20.8M | ||
| Q3 24 | — | $27.2M | ||
| Q2 24 | — | $31.6M |
股东权益HAEPLPC
| Q1 26 | $796.3M | — | ||
| Q4 25 | $911.5M | $475.5M | ||
| Q3 25 | $849.2M | $466.3M | ||
| Q2 25 | $882.3M | $460.7M | ||
| Q1 25 | $820.8M | $435.8M | ||
| Q4 24 | $906.9M | $422.3M | ||
| Q3 24 | $878.9M | $429.0M | ||
| Q2 24 | $905.4M | $416.2M |
总资产HAEPLPC
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.5B | $653.6M | ||
| Q3 25 | $2.4B | $644.6M | ||
| Q2 25 | $2.5B | $631.5M | ||
| Q1 25 | $2.5B | $592.5M | ||
| Q4 24 | $2.5B | $573.9M | ||
| Q3 24 | $2.5B | $592.0M | ||
| Q2 24 | $2.5B | $572.6M |
负债/权益比HAEPLPC
| Q1 26 | 1.53× | — | ||
| Q4 25 | 1.34× | 0.08× | ||
| Q3 25 | 1.44× | 0.08× | ||
| Q2 25 | 1.39× | 0.07× | ||
| Q1 25 | 1.49× | 0.07× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.08× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $293.2M | $21.9M |
| 自由现金流经营现金流 - 资本支出 | $209.9M | $11.8M |
| 自由现金流率自由现金流/营收 | 60.6% | 6.8% |
| 资本支出强度资本支出/营收 | 9.5% | 5.9% |
| 现金转化率经营现金流/净利润 | 3.01× | 2.60× |
| 过去12个月自由现金流最近4个季度 | $417.1M | $33.3M |
8季度趋势，按日历期对齐
经营现金流HAEPLPC
| Q1 26 | $293.2M | — | ||
| Q4 25 | $93.6M | $21.9M | ||
| Q3 25 | $111.3M | $18.9M | ||
| Q2 25 | $17.4M | $26.9M | ||
| Q1 25 | $116.6M | $5.7M | ||
| Q4 24 | $43.8M | $24.1M | ||
| Q3 24 | $48.8M | $9.4M | ||
| Q2 24 | $-27.4M | $28.3M |
自由现金流HAEPLPC
| Q1 26 | $209.9M | — | ||
| Q4 25 | $87.2M | $11.8M | ||
| Q3 25 | $106.3M | $8.3M | ||
| Q2 25 | $13.6M | $18.6M | ||
| Q1 25 | $100.9M | $-5.3M | ||
| Q4 24 | $35.2M | $20.6M | ||
| Q3 24 | $39.4M | $5.8M | ||
| Q2 24 | $-33.1M | $24.6M |
自由现金流率HAEPLPC
| Q1 26 | 60.6% | — | ||
| Q4 25 | 25.7% | 6.8% | ||
| Q3 25 | 32.5% | 4.7% | ||
| Q2 25 | 4.2% | 10.9% | ||
| Q1 25 | 30.5% | -3.6% | ||
| Q4 24 | 10.1% | 12.3% | ||
| Q3 24 | 11.4% | 3.9% | ||
| Q2 24 | -9.8% | 17.7% |
资本支出强度HAEPLPC
| Q1 26 | 9.5% | — | ||
| Q4 25 | 1.9% | 5.9% | ||
| Q3 25 | 1.5% | 6.0% | ||
| Q2 25 | 1.2% | 4.9% | ||
| Q1 25 | 4.7% | 7.4% | ||
| Q4 24 | 2.5% | 2.1% | ||
| Q3 24 | 2.7% | 2.4% | ||
| Q2 24 | 1.7% | 2.7% |
现金转化率HAEPLPC
| Q1 26 | 3.01× | — | ||
| Q4 25 | 2.09× | 2.60× | ||
| Q3 25 | 2.88× | 7.21× | ||
| Q2 25 | 0.51× | 2.12× | ||
| Q1 25 | 2.01× | 0.49× | ||
| Q4 24 | 1.17× | 2.30× | ||
| Q3 24 | 1.44× | 1.22× | ||
| Q2 24 | -0.71× | 3.02× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
PLPC
暂无分部数据
